{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 6 of 6 results
Status:
US Approved Rx
(1958)
Source:
NDA011366
(1958)
Source URL:
First approved in 1958
Source:
NDA011366
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.
Status:
Investigational
Source:
INN:sulocarbilate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sulocarbilate (also known as W-1548-1) is a sulfanilamide derivative and carbonic anhydrase inhibitor with diuretic activity. In preclinical models, Sulocarbilate shows similar efficacy and superior safety profile compared to other agents of this type. Clinically, Sulocarbilate shows the maximum effect as a natriuretic agent in an oral daily dose of 2 g.
Status:
US Previously Marketed
Source:
HYDROMOX by LEDERLE
(1963)
Source URL:
First approved in 1963
Source:
HYDROMOX by LEDERLE
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Quinethazone (brand name Hydromox) is a thiazide diuretic used to treat hypertension. The antihypertensive mechanism of quinethazone is less well understood. This drug was discovered in a period when only isoform carbonic anhydrases (CAs) II was known and considered physiologically/pharmacologically relevant. Recently was studied that quinethazone considerably inhibit other isozymes known nowadays to be involved in critical physiologic processes. Thiazides like quinethazone also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. Common side effects include dizziness, dry mouth, nausea, and low potassium levels. Thiazides may increase the toxicity of allopurinol, anesthetics, antineoplastic, calcium salts, diazoxide, digitalis, lithium; loop diuretics, methyldopa, nondepolarizing muscle relaxants, vitamin D; amphotericin B and anticholinergics may increase the toxicity of thiazides.
Status:
US Previously Marketed
Source:
ETHAMIDE by ALLERGAN
(1966)
Source URL:
First approved in 1957
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ethoxzolamide is a carbonic anhydrase I inhibitor. It is used in the treatment of glaucoma and duodenal ulcers, and as a diuretic. Ethoxzolamide was marketed under trade name Cadrase, but is now discontinued.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Clofenamide is a benzenedisulfonamide-based agent and carbonic anhydrase (CA) inhibitor with diuretic activity. Clofenamide inhibits CA, thereby preventing sodium, bicarbonate and thus water reabsorption in the proximal convoluted tubule resulting in diuresis.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Mefruside is a benzene disulfonamide derivative related to the benzothiadiazine or thiazide diuretics. Mefruside is adminisered orally, it is indicated for the treatment of edema and hypertension. It was developed by Bayer A.G. and is sold under the tradename Baycaron.